An interventional study of i-STAT TBI Test in Traumatic Brain Injury, sponsored by Icahn School of Medicine at Mount Sinai. Terminated at 3 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-15.
Sponsored by Icahn School of Medicine at Mount Sinai · Not applicable, Interventional, and Diagnostic
Study was terminated early due to recruitment limitations and available funding for continued recruitment and follow up
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai — 2 open to participants now, 2 under way, none of them phase 3. Brain Injuries, Traumatic · Icahn School of Medicine at Mount Sinai.
Among the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai, this one is the 9th largest by enrollment, is the only one that started in 2025, is one of 9 with no phase, and was the 10th registered.
1,725 studies on the registry are indexed under Brain Injuries, Traumatic; 450 are open to participants now.
Browse Brain Injuries, Traumatic studies →2 of the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai are open now, in 1 country. Recruiting first, the newest first:
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 18+ · Healthy volunteers
Icahn School of Medicine at Mount Sinai · Sites in United States
Ages 16+
By country, each count listing its studies:
Of the 287 Brain Injuries, Traumatic studies recruiting now, 126 (44%) set no upper age limit and 119 (41%) stop at 75 or younger; 41 take children under 18; 53 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
11 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 1 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 42 is below the median of 52 across 1,091 interventional studies indexed under Brain Injuries, Traumatic.
Median enrollment 77 across the 11 interventional studies. Of the 9 that completed or were terminated, 2 (22%) have results posted.
This tab as a report to print or save as PDF → With an account.
Icahn School of Medicine at Mount Sinai is the lead sponsor of 776 studies on the registry; 175 are open to participants now.
Of its 125 completed or terminated interventional studies of FDA-regulated products, 83 (66%) have results posted.
2 of the studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07600320Icahn School of Medicine at Mount SinaiFareon Open Label Device Clinical Trial | 2027-04-30 |
| NCT05933629Icahn School of Medicine at Mount SinaiCommunity-based Implementation of Online EmReg | 2027-08-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 11 studies in Brain Injuries, Traumatic by Icahn School of Medicine at Mount Sinai, from their registry updates:
This tab as a report to print or save as PDF → With an account.
According to the Centers for Disease Control and Prevention, approximately 200,000 hospitalizations occurred in 2020 related to Traumatic Brain Injury (TBI), which does not include many TBIs treated only in emergency departments, urgent care, primary care, or that are not evaluated by a clinician. Head CT is a critical component of care for severe TBI, however in mild TBI there is practice variation with a wider risk to benefit estimation for obtaining head CT imaging. Potential disadvantages of head CT include longer Emergency Department (ED) length of stay (LOS), higher costs, and diagnostic radiation exposure. The i-STAT TBI test is a panel of in vitro diagnostic immunoassays for the quantitative measurements of glial fibrillary acidic protein (GFAP) and ubiquitin carboxyl-terminal hydrolase L1 (UCH-L1) in whole blood and a semi-quantitative interpretation of test results derived from these measurements, using the i-STAT Alinity instrument. This biomarker test is cleared for use in adults with mild TBI (Glasgow Coma Scale 13-15) within 24 hours of injury, to aid in determining the need for head CT imaging. Currently, CT head imaging for adults with suspected mild TBI is obtained based on clinicians' usual practice patterns and beliefs about patient expectations. Prior research has demonstrated the blood TBI test may reduce unnecessary CT scans by up to 40%, however the impact on head CT ordering has not yet been studied prospectively. It is important to understand the extent to which a negative TBI biomarker result empowers a clinician to cancel a previously ordered head CT. Given that adult patients with mild TBI often present to EDs, which have access to CT scanners, this is a key setting to assess real-world impact of the i-STAT TBI test on CT head utilization.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
The ED clinicians caring for the enrolled patient, along with the patient, receive the TBI blood test result with just-in-time education on the TBI test to aid in clinical decision making.
Device: i-STAT TBI Test
Clinicians and enrolled patients do not receive the TBI blood test result.
The Abbott i-STAT TBI test result is shared with the enrolled patient and treating clinicians.
Also known as: Abbott iSTAT Alinity
Number of Head CT scans canceled
Number of head CTs canceled in patients not on anticoagulants as measurement of percentage of reduction in the number of canceled head CTs out of total head CTs ordered (total number and percentage)
Time frame: Within 24 hours of Traumatic Brain Injury
Subset of Number of Head CT scans completed
If the i-STAT TBI test results had been strictly adhered to by clinicians, subset of negative i-STAT TBI test results, Potential reduction in the number of completed head CTs (canceled) out of total head CTs ordered (total number and percentage)
Time frame: Within 24 hours of Traumatic Brain Injury
ED Length of Stay
Length of stay for the Emergency Department patient encounter
Time frame: Day 1 after patient ED care visit has ended
Number of cancellations of head CT scan order in patients on anticoagulants
Number of cancellations in head CTs in patients on anticoagulation
Time frame: Day 1 after patient ED care visit has ended
Patient Satisfaction Scale
Assessment of patient satisfaction with care during ED visit. Full scale from 1 (worst care possible) to 10 (best care possible)
Time frame: At 14 days after ED visit
Number of head CT scans completed
Number of head CT scans completed for patients within 14 days after index ED visit
Time frame: At 14 days after ED visit
Stress of Uncertainty Scale (SUS)
Clinicians vary in their use of diagnostic testing and treatments, and stress of uncertainty may be one explanation for this variation. The stress of uncertainty scale measures clinician tolerance of uncertainty during patient care. SUS scores range from 15-90 with a higher score indicating greater fear of uncertainty.
Time frame: Day 1 during patient ED care visit
Malpractice Fear Scale (MFS) Scores
Malpractice Fear Scale (MFS) scores. MFS scores range from 6 to 36 with a higher score indicating greater fear of malpractice.
Time frame: Day 1 during patient ED care visit
Whole blood concentrations of GFAP (glial fibrillary acidic protein)
Whole blood concentrations for GFAP on the iSTAT device. Biomarker for use with mild TBI within 24 hours of injury to aid in determining the need for head CT imaging.
Time frame: Day 1 during patient ED care visit
Whole blood concentrations of UCH-L1 (ubiquitin C-terminal hydrolase L1)
Whole blood concentrations for UCH-L1 on the iSTAT device. Biomarker for use with mild TBI within 24 hours of injury to aid in determining the need for head CT imaging.
Time frame: Day 1 during patient ED care visit
Plan to share: No — There is no plan to share IPD at this time.
No publications or documents are linked to this record.
Ran from Jan 2025 to primary completion in Mar 2026, 14 months.
Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 15, 2026: primary completion Sep 2025 → Mar 2026 and completion Oct 2025 → May 2026.
Earlier changes are on the record history on ClinicalTrials.gov ↗
How these figures are worked out, and which studies are left out of them.
Study was terminated early due to recruitment limitations and available funding for continued recruitment and follow up
Study was terminated early due to recruitment limitations and available funding for continued recruitment and follow up
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is terminated, as verified in Oct 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Icahn School of Medicine at Mount Sinai →